The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“Ampli®cation and overexpression of the HER2 gene occurs in 30% of breast tumors and a signi®cant number of other cancers (Slamon et al., 1987, 1989; Tal et al., 1988).”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,826
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130 · cited 2×
“Akt regulates both the translation and stability of cyclin D-protein (Diehl et al., 1998; Muise-Helmericks et al., 1998).”
BackgroundFranke, T. F., Yang, S.-I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., & Tsichlis, P. N. (1995) · Cell · doi:10.1016/0092-8674(95)90534-0 · Cited by 2,006
The PI3K‒PDK1 connection: more than just a road to PKB
Vanhaesebroeck, B., & Alessi, D. R. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3460561 · Cited by 1,644
Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.7732382 · Cited by 1,583 · cited 2×
“Lactacystin is a speci®c irreversible inhibitor of the 20S proteasome (Fenteany et al., 1995).”
BackgroundBaselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Modulation of Akt kinase activity by binding to Hsp90
Sato, S., Fujita, N., & Tsuruo, T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170276797 · Cited by 967
Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., & Slamon, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202526 · Cited by 692
PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond
Marte, B. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(97)01097-9 · Cited by 689
Skorski, T., Bellacosa, A., Nieborowska‐Skorska, M., Majewski, M., Martinez, R., Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O., et al. (1997) · The EMBO Journal · doi:10.1093/emboj/16.20.6151 · Cited by 567
Muise-Helmericks, R. C., Grimes, H. L., Bellacosa, A., Malstrom, S. E., Tsichlis, P. N., & Rosen, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.45.29864 · Cited by 511
Self-citationMammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4
Stepanova, L., Leng, X., Parker, S. B., & Harper, J. W. (1996) · Genes & Development · doi:10.1101/gad.10.12.1491 · Cited by 483 · cited 2×
“Hsp90 is involved in the stabilization of cdk4, a protein targeted by the ansamycins (Stepanova et al., 1996).”
BackgroundMimnaugh, E. G., Chavany, C., & Neckers, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22796 · Cited by 466
Pratt, W. B. (1998) · Experimental Biology and Medicine · doi:10.3181/00379727-217-44252 · Cited by 447
Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch, C., Weiss, F. U., Niederfellner, G., Jallal, B., Issing, W., & Ullrich, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00101.x · Cited by 406
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
Schneider, C., Sepp-Lorenzino, L., Nimmesgern, E., Ouerfelli, O., Danishefsky, S., Rosen, N., & Hartl, F. U. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14536 · Cited by 405
Self-citationXu, W., Mimnaugh, E., Rosser, M. F. N., Nicchitta, C., Marcu, M., Yarden, Y., & Neckers, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006864200 · Cited by 353
Casamayor, A., MORRICE, N. A., & Alessi, D. R. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3420287 · Cited by 345
Wennström, S., & Downward, J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.6.4279 · Cited by 277
Schulte, T. W., Blagosklonny, M. V., Romanova, L., Mushinski, J. F., Monia, B. P., Johnston, J. F., Nguyen, P., Trepel, J., & Neckers, L. M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5839 · Cited by 269
Whitesell, L. (1996) · Molecular Endocrinology · doi:10.1210/me.10.6.705 · Cited by 263
Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis.
Page, C., Lin, H., Jin, Y. H., et al. (2000) · PubMed · Cited by 220
Stancato, L. F., Silverstein, A. M., Owens-Grillo, J. K., Chow, Y.-H., Jove, R., & Pratt, W. B. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4013 · Cited by 200
Münster, P. N., Basso, A., Solit, D., Norton, L., & Rosen, N. (2001) · PubMed · Cited by 173
Self-citationWebb, C. P., Hose, C. D., Koochekpour, S., Jeffers, M., Oskarsson, M. K., Sausville, E. A., Monks, A. P., & Woude, G. F. V. (2000) · PubMed · Cited by 168
ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase
Hellyer, N. J., Cheng, K., & Koland, J. G. (1998) · Biochemical Journal · doi:10.1042/bj3330757 · Cited by 144
Czar, M. J., Galigniana, M. D., Silverstein, A. M., & Pratt, W. B. (1997) · Biochemistry · doi:10.1021/bi970648x · Cited by 141 · cited 2×
“Ansamycins cause the degradation of a subset of proteins that require Hsp90 for conformational maturation (Czar et al., 1997; Mimnaugh et al., 1996; Pratt, 1998; Schulte et al., 1996; Stancato et al., 1997; Webb et al., 2000; Whitesell and Cook, 1996).”
BackgroundInhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
Srethapakdi, M., Liu, F., Tavorath, R., & Rosen, N. X. (2000) · PubMed · Cited by 136
Self-citationSporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues.
Tal, M., Wetzler, M., Josefberg, Z., et al. (1988) · PubMed · Cited by 133
Transformation by v-Src: Ras-MAPK and PI3K-mTOR Mediate Parallel Pathways
Penuel, E. M., & Martin, G. S. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.6.1693 · Cited by 131
Bardelli, A., Basile, M. L., Audero, E., Giordano, S., Wennström, S., Ménard, S., Comoglio, P. M., & Ponzetto, C. (1999) · Oncogene · doi:10.1038/sj.onc.1202607 · Cited by 78
Cited by
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
“Breast cancers with HER2 amplification have elevated levels of AKT and ERK phosphorylation and are dependent on the former, but not the latter for maintenance of the transformed phenotype (Basso et al., 2002; Hermanto et al., 2001; She et al., 2008; Solit et al., 2006).”
Self-citationHolbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 950
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Neckers, L., & Workman, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1000 · Cited by 891
Metadata
- Authors
- Basso, A. D., Solit, D. B., Munster, P. N., & Rosen, N.
- Venue
- Oncogene
- Published
- 2002-02-14
- Volume
- 21
- Issue
- 8
- Pages
- 1159-1166
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2001215449
- Cited by
- 265
- References
- 38
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.